Kornimate/medical-research-clean huggingface dataset:
survival outcomes of lung cancer

Conditions: Lung Cancer

Summary: this is a prospective study to analyze the survival outcomes of different groups about lung cancer patients.

this study aims to analyze the survival outcomes of different groups about lung cancer patients. all the groups were assessed to the treatment decisions guided by molecular profiling and clinical judgment of principal investigators

Eligibility criteria:
inclusion criteria: 1. understand the requirements and contents of the clinical trial . 2. age ≥ 18 years. 3. histopathology or cytology confirmed lung cancer 4. ecog \<=2. 5. predicted survival ≥ 12 weeks. 6. adequate bone marrow hematopoiesis and organ function 7. presence of measurable lesions according to recist 1.1. exclusion criteria: 1. subjects who have received any of the following treatments must be excluded: * have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity. chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose. * ongoing (or inability to discontinue) possibly potent cyp1a2, cyp3a inhibitor (1 week), or inducer (2 weeks) drug therapy or herbal supplements within 1-2 weeks prior to the first dose. 2. presence of spinal cord compression or meningeal metastasis. 3. history of other malignant tumors within 2 years. 4. adverse events (except alopecia of any degree) of ctcae \> grade 1 due to prior treatment (e.g., adjuvant chemotherapy, radiotherapy, etc.) prior to the first dose. 5. history of stroke or intracranial hemorrhage within 6 months prior to the first dose. 6. the presence of any severe or poorly controlled systemic disease, including poorly controlled hypertension and active bleeding in the judgment of the investigator. 7. subjects with persistent or active infection, including but not limited to hepatitis b (hbv), hepatitis c (hcv), human immunodeficiency virus (hiv) and covid-19 infection. 8. heart-related diseases or abnormalities 9. past history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or interstitial lung disease with active clinical symptoms, immune pneumonia caused by immunotherapy. 10. refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing drugs, or inability to adequately absorb drugs due to previous bowel resection. 11. live vaccine was given 2 weeks before the first medication. 12. women who are breastfeeding or pregnant. 13. hypersensitivity to the test drug and the ingredients. 14. other conditions assessed by the investigator to be unsuitable for participation in the study.
a study of trimetrexate in the treatment of pneumocystis carinii pneumonia (pcp) in patients with aids not previously treated for pcp

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: to evaluate the safety and effectiveness of trimetrexate (tmtx) given at increasing doses along with the leucovorin calcium (lcv) for treating pneumocystis carinii pneumonia (pcp) in aids patients tmtx is an experimental new drug which is effective for treatment of pcp, but has been given to only a few patients. therefore it is not certain if tmtx is better, the same as, or not as effective as conventional drugs against pcp.

tmtx is an experimental new drug which is effective for treatment of pcp, but has been given to only a few patients. therefore it is not certain if tmtx is better, the same as, or not as effective as conventional drugs against pcp. increasing doses of tmtx are used in combination with lcv as initial treatment for pcp in 50 aids patients. doses are increased for 21 days on a once daily and then a twice daily basis. dose escalations occur in subsequent groups of patients.

Eligibility criteria:
inclusion criteria patient must: * have pneumocystis carinii pneumonia (pcp) that has not been treated for current episode. pcp must be documented by observation of \> 1 cluster of organisms in sputum, bronchial secretion, or lung tissue. * have clinical symptoms of respiratory disease or radiologic abnormalities. exclusion criteria * patient cannot have significant emotional disorder. concurrent medication: excluded: * drugs likely to be bone marrow toxic. * investigational drugs. prior medication: excluded: * three patients in each group cannot have had zidovudine (azt) for at least 2 months prior to administration of trimetrexate.

Keywords: trimetrexate aids-related opportunistic infections pneumonia, pneumocystis carinii injections, intravenous leucovorin dose-response relationship, drug drug therapy, combination folic acid antagonists administration, oral acquired immunodeficiency syndrome antineoplastic agents
a phase 1 study to assess hm15275 in healthy and obese subjects.

Conditions: Obesity

Summary: this study is a phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of hm15275 in healthy and obese subjects.


Eligibility criteria:
inclusion criteria: 1. female and male adults, ages ≥ 18 and ≤ 65 years. 2. part a: healthy subjects with body mass index (bmi) ≥ 20.0 kg/m2 and ≤ 27 kg/m2. part b: obese subjects with bmi ≥ 30.0 kg/m2 and ≤ 45.0 kg/m2 with a stable body weight for 3 months prior to screening (defined as change \< 5%). 3. hba1c \< 6.5 % \[based on american diabetes association, 2023\]. 4. female subjects must be non-pregnant and non-lactating. 5. subjects must be able to provide written informed consent and are willing to follow study procedures and commitment to the study duration. exclusion criteria: 1. subject with existence of any surgical or medical condition that, in the judgment of the investigator, might interfere with the absorption, distribution, metabolism or excretion of the investigational product. 2. active or untreated malignancy or has been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for \< 5 years. 3. subjects with a history of any serious adverse reaction or hypersensitivity to study drug components (includes glp-1, gip, glucagon analogs) or have contraindicating diseases. 4. subjects with confirmed type 1 or type 2 diabetes. 5. subject is unwilling to avoid consumption of coffee and caffeine-containing beverages within from 24 hours before each study visit and while subjects are confined to the study center. 6. subject is unwilling to abstain from vigorous exercise from 48 hours prior to admission until the follow-up visit. 7. history of alcohol abuse as judged by the investigator within approximately 1 year prior to screening. 8. history of regular use (defined as ≥ 10 cigarettes per day) of nicotine-containing products (including but not limited to cigarettes, e-cigarettes, pipe, chewing tobacco, nicotine patch or gum) or vaping products within 6 weeks prior to check-in for the first in-house period.

Keywords: obesity
a multicenter, international, follow-up study to monitor the efficacy and safety of the occlutech® pmvsd occluder in patients with perimembranous ventricular septal defects

Conditions: Perimembranous Ventricular Septal Defect

Summary: the objective of this registry is to gain more insight on the clinical use of the occlutech perimembranous vsd occluder.


Eligibility criteria:
inclusion criteria: patients with haemodynamically significant perimembranous defects which are located in the ventricular septum exclusion criteria: occlutech® pmvsd occluder is contraindicated for the following: * patients with defects less than 2 mm aortic rim and/or interference with the aortic or atrioventricular valves * patients less than 10.0 kg * patients with sepsis (local or generalized) * patients with left ventricle to right atrial shunting * patients with right to left shunting through the defect * patients with pmvsd with an aneurysm and multiple shunts that could not be successfully closed with one device * patients with complex heart lesions such as tetralogy of fallot * history of repeated pulmonary infection * any type of serious infection 1 month prior to procedure * malignancy where life expectancy is less than 3 years * demonstrated intracardiac thrombi on echocardiography * patients with allergy to anti-platelet or anticoagulant therapy * patients with allergy to nickel and/or titanium and/or nickel/titanium based materials * patients with intolerance to contrast agents * patients with active bacterial infections * patients with very small vessels which are not suitable for recommended delivery sheath sizes
improving stroke care in north-norway through artificial intelligence

Conditions: Ischemic Stroke

Summary: prospective observational multi-center intervention study. the study aims to evaluate whether an artificial intelligence (ai) support tool for radiological image processing (strokesens, circle nvi) can accelerate decision making and increase detection rate in patients with an acute ischemic stroke caused by intracranial large vessel occlusion (lvo) or medium vessel occlusion (mevo) in northern norway. relevant outcomes will be compared between centres with and without available software during the study period.

this study aims to evaluate whether an ai support tool (strokesens, circle nvi) can accelerate decision making and increase detection rate in patients with an acute ischemic stroke caused by intracranial large vessel occlusion (lvo) or medium vessel occlusion (mevo) in northern norway. the software will be a decision support tool in addition to standard radiological services where image interpretation is done by a radiologist or resident in radiology. the ai-tool will be available in 5 of 10 primary hospitals in northern norway. the ai-software employed in this study can automatically evaluate the presence of ischemic changes in the vascular territory of the middle cerebral artery according to the alberta stroke program early ct score (aspects) and detect occlusions in the intracranial segment of the internal carotid artery and the proximal segments of the middle cerebral artery (mca). the main goal of this project is to evaluate if access to the ai-software: 1. accelerates identification and handling of stroke patients harbouring an intracranial lvo. 2. leads to a higher detection rate of anterior circulation lvo and mevo. the secondary goal is to evaluate: 1. if ai software leads to a higher number of thrombectomy treated lvo and mevo patients. 2. if ai software may lead to improved patient outcomes. hypothesis: implementation of ai-based image analysis software as a decision support tool for radiologists, reduces time from imaging to transfer request in patients harbouring lvo/mevo, and increases detection rate of large and medium sized vessel intracranial occlusion compared to the present day practices in primary stroke centres within the health region. all outcomes will be a compared between primary stroke centres with and without access to the ai-software and historical data from the same sites as collected prior to software implementation (2019-2022).

Eligibility criteria:
inclusion criteria: * patients with acute stroke symptoms admitted to a participating hospital within 24 hours of symptom onset exclusion criteria: * patients not available for follow-up assessments (e.g. non-resident)

Keywords: large vessel occlusion artificial intelligence thrombectomy interhospital transfer medium sized vessel occlusion
high and low level laser therapy in de quervain's tenosynovitis

Conditions: DeQuervain Tendinopathy

Summary: the aim in this study was to compare the effects of high and low power laser treatments in the treatment of de quervein tenosynovitis clinically and ultrasonographically.

de quervain's tenosynovitis is tenosynovitis of the abductor pollicis longus (apl) and extensor pollicis brevis (epb) tendons. conservative management includes nonsteroidal anti-inflammatory drugs, wrist and thumb immobilization, ultrasound, and low-level laser therapy (lllt). according to early literature, low-level laser therapy and ultrasound therapy appear to produce similar biological effects in reducing inflammation and promoting tissue healing. in a study low-power laser therapy was found to be effective compared to placebo in de quervain's tenosynovitis. in a study of 35 female patients, low-power laser therapy (lllt) combined with a thumb-supported splint was not superior to splint alone in patients with de quervain's tenosynovitis. in a more recent study low-power laser therapy was found to be similarly effective to ultrasound therapy. the investigators found no studies in the literature on the effect of high-power laser therapy. the aim in this study was to compare the effects of high and low power laser treatments in the treatment of de quervein tenosynovitis clinically and ultrasonographically.

Eligibility criteria:
inclusion criteria: * between18-65 years of age * wrist pain for more than 3 weeks * finkelstein test positive * ability to understand commands exclusion criteria: * physical therapy, injections, or surgery in the upper extremity in the last 3 months * fracture or trauma in the upper extremity in the last 6 months * radiating pain due to cervical discopathy * infection, loss of sensation, metal implant in the treatment area * inflammatory rheumatic diseases * nsaid use * pregnancy or planning pregnancy during treatment * malignancy * pathology in the wrist on radiograph
study evaluating desvenlafaxine succinate sustained release in adults with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with major depressive disorder. the study will also assess changes in sexual function and general and functional quality of life outcomes.


Eligibility criteria:
inclusion criteria: * adult, outpatient with primary diagnosis of major depressive disorder (depressive symptoms for at least 30 days prior to screening). * hamilton psychiatric rating scale for depression (ham-d 17) total score of \>= 20. * clinical global impressions scale-severity (cgi-s) score of \>= 4. exclusion criteria: * clinical instability (25% or greater increase/decrease in ham-d 17 total score from screening to baseline). * significant risk of suicide as assessed by clinician judgment, ham-d 17 and columbia suicide-severity rating scale scores other eligibility criteria also apply.

Keywords: major depressive disorder
chylothorax following heart surgery

Conditions: Chylothorax

Summary: the purpose of this study is to determine at risk populations for certain congenital heart defects or certain operative procedures and to define the associated morbidity secondary to chylothorax - prolonged chest tube drainage, prolonged hospital stay, need for central access and hyperalimentation, subsequent infection.

chylothorax is not uncommon following congenital heart surgery. it often results in prolonged chest tube drainage and hospital stays. due to the feeding difficulties, it often results in malnutrition and the need for central hyperalimentation. in addition, it results in a depressed immune system with the possibility of subsequent infection. chylothorax can be a significant contributor to post-operative morbidity and mortality. the primary aims are to determine at risk populations - certain congenital heart defects or certain operative procedures, to define the associated morbidity secondary to chylothorax - prolonged chest tube drainage, prolonged hospital stay, need for central access and hyperalimentation, subsequent infection and to review our current treatment methods - change formulas, hyperalimentation, somatostatin. the secondary aims are to determine ways to prevent chylothorax, determine the most successful treatment method, and to discover better treatment methods. this study will be conducted through a retrospective chart review.

Eligibility criteria:
inclusion criteria: * patients in the congenital surgery database * patients have developed post-operative chylous effusions exclusion criteria: -

Keywords: pediatric health cardiac congenital heart surgery post-operative chylous effusions heart defects children
a study to assess the clinical efficacy of donidalorsen (also known as ionis-pkk-lrx and isis 721744) in participants with hereditary angioedema

Conditions: Hereditary Angioedema

Summary: the purpose of this study was to evaluate the clinical efficacy, safety, and tolerability of donidalorsen in participants with hereditary angioedema (hae) type 1 (hae-1), hae type 2 (hae-2), or hae with normal c1-inhibitor (c1-inh) and to evaluate the effect of donidalorsen on plasma prekallikrein (pkk) and other relevant biomarkers.

this was a randomized, double-blind, placebo-controlled study in 23 participants conducted concurrently in 2 parts (part a and part b); participants were allocated into part a or part b according to type of hae (i.e., either hae-1/hae-2 in part a or hae-nc1-inh in part b). part a was randomized, double-blind, and placebo-controlled; and part b was open-label. the length of participation in the study was approximately 8 months, which included an up to 8-week screening period, a 12-week treatment period, and a 13-week post-treatment period.

Eligibility criteria:
inclusion criteria: * documented diagnosis of hae-1/hae-2 (for inclusion in part a) or hae-nc1-inh (for inclusion in part b) * participants must have experienced a minimum of 2 hae attacks (assessed by the angioedema activity score \[aas\] and confirmed by the investigator) during the screening period * access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks exclusion criteria: * anticipated use of short-term prophylaxis for angioedema attacks for a pre-planned procedure during the screening or study periods * concurrent diagnosis of any other type of recurrent angioedema, including acquired or idiopathic angioedema * known history of or positive test for human immunodeficiency virus (hiv), hepatitis c, or chronic hepatitis b * malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated * treatment with another investigational drug or biological agent within 1 month or 5 half-lives, whichever is longer, of screening * exposure to any of the following medications: * angiotensin-converting enzyme (ace) inhibitors or any estrogen-containing medications with systemic absorption (such as oral contraceptive or hormonal replacement therapy) within 4 weeks prior to screening * chronic prophylaxis with lanadelumab within 10 weeks prior to screening * oligonucleotides (including small interfering ribonucleic acid \[rna\]) within 4 months of screening (if single dose received) or within 12 months of screening (if multiple doses received)

Keywords: ionis pkk-lrx donidalorsen
pegylated liposomal doxorubicin containing chemotherapy in the treatment of older non-hodgkin's lymphoma patients

Conditions: Non-Hodgkin's Lymphoma

Summary: currently there is no one standard of care for older patients with non-hodgkin's lymphoma (nhl). the study will examine the tolerability and feasibility to the combination of cyclophosphamide, pegylated liposomal doxorubicin, vincristine, prednisone (cdop) plus rituximab.

elderly nhl patients tend to tolerate the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (chop) less well when compared to the younger population. cardiotoxicity, as well as neutropenia, are the most common side effects in the elderly population with age being a risk factor for doxorubicin induced cardiac toxicity. treatment related toxicity in the older population can preclude adequate therapy and potentially contribute to poor outcomes. pegylated liposomal doxorubicin has shown similar efficacy with a significant lower incidence of cardiotoxicity ad significantly fewer cardiac events compared with conventional doxorubicin. exploration of alternative regimens to maximize tolerability and thus enhance overall efficacy in this population is warranted. both safety and efficacy will be evaluated.

Eligibility criteria:
inclusion criteria: * age 65 years and older; * diagnosis of non-hodgkin's lymphoma where therapy with chop plus rituximab is considered; * previously untreated; * ecog 0-2 * adequate renal and hepatic functions; * cardiac ejection fraction at least 50% by muga. no significant cardiac abnormalities by ekg; * signed informed consent exclusion criteria: * cns involvement by lymphoma; * hypersensitivity to study drugs; * active infection; * prior treatment with monoclonal antibodies for cancer; * history of cardiac disease with new york heart association class ii or greater or clinical evidence of congestive heart failure

Keywords: nhl elderly
clinical trial on acupuncture therapy in patients with gastrointestinal neoplasms laparoscopic surgery

Conditions: Gastrointestinal Neoplasms

Summary: patients accepted laparoscopic radical operation for carcinoma of colon and upper middle section of the rectum will be as the research object. cancer patients are diagnosed based on pathology or cell biology. the trial is randomized, parallel and open. they are randomized into 2 groups: both groups receive surgery. the experimental group receives conventional treatment combine with electroacupuncture zusanli point .etc finish operation and the contrast receives the same conventional treatment with experimental group. clinical evaluation includes gastrointestinal tract recovery of function, pain relief, life quality improvement. blood biochemistry tests mainly include gastrin(gas), stress related hormone, peroxidatic reaction and the ratio of immune cells.


Eligibility criteria:
inclusion criteria: * weight: 40kg-90kg, male and female. * diagnosis: imaging, cell and pathology report. * brain, heart, lung, liver, kidney are at good condition in 2 weeks before surgery. * no conscious obstacle and limbs disability. exclusion criteria: * fainting during acupuncture. * electrolyte imbalance. * serious and life-threatening complications after surgery. * in addition, patients taking part in other clinical trials, being treated with other biotherapy or immunotherapy and researchers consider not suitable for clinical subjects for other reasons will be excluded.

Keywords: acupuncture therapy laparoscopic surgery gastrointestinal tract recovery of function
comparison study of lay person finger stick versus blood draw

Conditions: Diabetes

Summary: this is a study to evaluate the safety and effectiveness of micro-serum/micro-blood (finger stick) specimen collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).

this is a study to evaluate the safety and effectiveness of micro-serum/micro-blood (finger stick) specimen collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein). the information and data obtained will be used to finish development of a convenience kit that allows doctors to provide their patients a method to have their blood tested for clinical laboratory tests in the convenience of their home without having to visit the doctor's office or clinic.

Eligibility criteria:
inclusion criteria: 1. ability to understand and follow verbal and written instructions in english 2. demonstrate a willingness to participate by providing a written informed consent 3. aged between 18 to 80 years of age with no obvious signs of illness (e.g. fever, vomiting) 4. diabetics who were diagnosed 6 months ago or longer are preferred. however, non-diabetics will be accepted into the study. exclusion criteria: 1. withdrawn informed consent 2. mental or physical impairment which would preclude participation 3. any condition which, in the opinion of the principle investigator or site or study coordinator, makes the participant unsuitable for this study. this includes but is not limited to any mental or physical impairment, which would preclude provision of adequate and knowledgeable consent.